The molecular categorization of BC is based on the evaluation of four clinically standardized biomarkers: estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and the proliferation marker Ki67 [1,6,7]. This evidence concerns the gene ERBB2 and breast cancer.